Kaklamanis L, Gatter K C, Mortensen N, Harris A L
Nuffield Department of Pathology, John Radcliffe Hospital, Headington, Oxford, UK.
Br J Cancer. 1992 Oct;66(4):712-6. doi: 10.1038/bjc.1992.343.
Interleukin-4 receptor (IL-4R) and Epidermal Growth Factor receptor (EGFR) were assessed as factors associated with adenoma-carcinoma progression in colorectal cancer and tumour invasion. A monoclonal antibody (MR6) was applied to detect IL-4R in: metaplastic polyps (five cases), adenomas (15 cases), and carcinomas (44 adenocarcinomas and one squamous cell). Positive labelling was obtained in all polyps, adenomas and in 40/45 carcinomas. Normal colonic mucosa of these patients, as well as macrophages and lymphocytes infiltrating the tumour stroma, were also positively labelled with MR6. Four out of five poorly differentiated adenocarcinomas did not show IL-4 receptor expression. No significant correlation was found with tumour size, lymph node stage and IL-4 receptor expression. On the above specimens a parallel detection of epidermal growth factor receptors (EGFR) by a monoclonal antibody (EGFR 1) was carried out. Expression of EGFR was found in 14/20 polyps and in 22/45 carcinomas. All but one of the EGFR positive malignant tumours showed coexpression of IL-4 receptor. Lymph node involvement by tumour cells was detected in 25 out of 45 patients. Eighteen of these 25 cases were positive with EGFR1.
白细胞介素-4受体（IL-4R）和表皮生长因子受体（EGFR）被评估为与结直肠癌腺瘤-癌进展及肿瘤侵袭相关的因素。应用一种单克隆抗体（MR6）检测IL-4R在以下组织中的表达：化生息肉（5例）、腺瘤（15例）和癌（44例腺癌和1例鳞状细胞癌）。在所有息肉、腺瘤以及40/45例癌中均获得阳性标记。这些患者的正常结肠黏膜以及浸润肿瘤基质的巨噬细胞和淋巴细胞也被MR6阳性标记。5例低分化腺癌中有4例未显示IL-4受体表达。未发现肿瘤大小、淋巴结分期与IL-4受体表达之间存在显著相关性。在上述标本上，通过一种单克隆抗体（EGFR 1）对表皮生长因子受体（EGFR）进行了平行检测。在14/20例息肉和22/45例癌中发现了EGFR表达。除1例EGFR阳性恶性肿瘤外，其余所有肿瘤均显示IL-4受体共表达。45例患者中有25例检测到肿瘤细胞累及淋巴结。这25例中有18例EGFR1呈阳性。
